Assessing Drug-Smoking Interactions Using PBPK Modeling Blog Assessing Drug-Smoking Interactions Using PBPK Modeling The prevalence of cigarette smoking remains high globally despite abundant evidence showing that it isn't…Certara2016 年 7 月 29 日
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 Publication Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6 Danielle Pillsbury2016 年 7 月 20 日
Model-based Meta-analysis: An Innovative Methodology Comes of Age White Paper 基于模型的荟萃分析(MBMA):创新方法的时代来临了 MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…Danielle Pillsbury2016 年 7 月 14 日
D360™ Scientific Informatics Platform for Drug Discovery and Development Brochure 用于药物发现和开发的 D360™ 科学信息平台 Discovery drug research requires understanding complex biological, chemical, logistical and computational data from a wide…Danielle Pillsbury2016 年 7 月 14 日
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment Publication Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients with Renal Impairment Avibactam is a non-β-lactam β-lactamase inhibitor intended for use as a fixed-dose combination with ceftazidime…Danielle Pillsbury2016 年 7 月 12 日
A Tutorial on Pharmacodynamic Scripting Facility in Simcyp Publication A Tutorial on Pharmacodynamic Scripting Facility in Simcyp The Simcyp® Simulator provides a framework for mechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic modelling of potentially interacting drugs.…Danielle Pillsbury2016 年 7 月 9 日
Status of QSP Modeling in the Pharmaceutical Industry Blog Status of QSP Modeling in the Pharmaceutical Industry A primary cause of failures in pharmaceutical research and development (R&D) has been attributed to…Certara2016 年 7 月 6 日
Physiologically-based Pharmacokinetic Modeling in Pediatric Oncology Drug Development Publication Physiologically-based Pharmacokinetic Modeling in Pediatric Oncology Drug Development Danielle Pillsbury2016 年 7 月 1 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Publication More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…Danielle Pillsbury2016 年 7 月 1 日
How Does the In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach Publication How Does the In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach Information on the developmental changes in biliary excretion (BE) of drugs is sparse. The aims…Danielle Pillsbury2016 年 7 月 1 日